Keywords: Riboxx Pharma, China National Biotec, Riboxxim, Vaccine adjuvant, Infectious diseases

Riboxx Pharma links with China National Biotec to evaluate Riboxxim as adjuvant in a vaccine

Article | 05 March 2013

Print This

Germany’s Riboxx Pharmaceuticals GmbH and China National Biotec Group (CNBG) say they have initiated a research collaboration to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in